

REMARKS

Attached hereto is a marked-up version of the changes made to the claims by the current amendment. The attached page is captioned "Version with markings to show changes made."

Applicants have amended the claims to put them in conformity with the U.S. practice.

No new matter has been introduced.

Respectfully submitted,



Yuriy P. Stercho, Ph.D.
Attorney for Applicants
Registration No. 33,797

SMITHKLINE BEECHAM CORPORATION
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, PA 19406-0939
Phone (610) 270-5018
Facsimile (610) 270-5073

n\yps\response\P31853C1\preamd.doc

PROHIBITED BY LAW FROM BEING COPIED

VERSION WITH MARKINGS TO SHOW CHANGES MADE

In the specification:

An Abstract of the Invention has been added.

In the claims:

Claims 4-12, 16, 18-20 and 22 have been amended as follows:

4. (Amended) A method according to [any one of] claim[s] 1 [to 3], wherein the insulin sensitiser is 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione (Compound I).

5. (Amended) A method according to [any one of] claim[s 1 to] 4, which comprises the administration of 2 to 12 mg of Compound (I).

6. (Amended) A method according to [any one of] claim[s 1 to] 5, which comprises the administration of 2 to 4, 4 to 8 or 8 to 12 mg of Compound (I).

7. (Amended) A method according to [any one of] claim[s 1 to] 6, which comprises the administration of 2 to 4mg of Compound (I).

8. (Amended) A method according to [any one of] claim[s 1 to] 6, which comprises the method the administration of 4 to 8mg of Compound (I).

9. (Amended) A method according to [any one of] claim[s 1 to] 6, which comprises the administration of 8 to 12 mg of Compound (I).

10. (Amended) A method according to [any one of] claim[s 1 to 6] 7, which comprises the administration of 2 mg of Compound (I).

11. (Amended) A method according to [any one of] claim[s 1 to 6] 8, which comprises the administration of 4 mg of Compound (I).

12. (Amended) A method according to [any one of] claim[s 1 to 6] 8, which comprises the administration of 8 mg of Compound (I).

16. (Amended) A composition according to claim 14 [or claim 15], wherein the insulin secretagogue is glibenclamide, glipizide, gliclazide, glimepiride,

EPO-201807041650

tolazamide or tolbutamide, acetohexamide, carbutamide, chlorpropamide, glibornuride, gliquidone, glisentide, glisolamide, glisoxepide, glyclopamide, glycylamide or repaglinide.

18. (Amended) A composition according to [any one of] claim[s] 14 [to 17], wherein the insulin sensitiser is 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)-ethoxy]benzyl]thiazolidine-2,4-dione (Compound I).

19. (Amended) A composition according to [any one of] claim[s] 14 [to 17], which comprises 2 to 12 mg of Compound (I).

20. (Amended) A pharmaceutical composition comprising an insulin sensitiser, an insulin secretagogue and a pharmaceutically acceptable carrier therefor, for use as an active therapeutic substance.

22. (Amended) A composition according to [any one of] claim[s] 14, [20 or 21,] wherein the insulin sensitiser is (+)-5-[[4-[(3,4-dihydro-6-hydroxy-2, 5, 7, 8-tetramethyl-2H-1-benzopyran-2-yl)methoxy]phenyl]methyl]-2,4-thiazolidinedione (or troglitazone), 5-[4-[(1-methylcyclohexyl)methoxy]-benzyl] thiazolidine-2,4-dione (or ciglitazone), 5-[4-[2-(5-ethylpyridin-2-yl)ethoxy]benzyl] thiazolidine-2,4-dione (or pioglitazone) or 5-[(2-benzyl-2,3-dihydrobenzopyran)-5-ylmethyl]thiazolidine-2,4-dione (or englitazone); or a pharmaceutically acceptable form thereof.

100-0216560